What are the best treatments for Uveitis?

The primary goal of treating uveitis is to reduce inflammation, alleviate pain, and prevent vision loss through a combination of topical, systemic, or injectable medications. Treatment is highly personalized based on the anatomical location of the uveitis (anterior, intermediate, posterior, or panuveitis) and whether the condition is infectious or autoimmune in nature.

What are the first-line treatments for uveitis?

For most patients, the first-line treatment for uveitis involves the use of corticosteroids to rapidly suppress ocular inflammation. Topical corticosteroid eye drops (such as prednisolone acetate or dexamethasone) are standard for anterior uveitis. If the inflammation is located in the back of the eye or is chronic, systemic corticosteroids (such as oral prednisone) may be required. Cycloplegic-mydriatic eye drops (such as cyclopentolate or atropine) are frequently prescribed alongside steroids to dilate the pupil, which prevents painful iris spasms and reduces the risk of synechiae (adhesions between the iris and the lens).

How is moderate-to-severe uveitis managed?

When uveitis is chronic, recurrent, or resistant to steroids, specialists often transition to steroid-sparing therapies to avoid the side effects of long-term corticosteroid use. These treatments include:

• Antimetabolites: Methotrexate, mycophenolate mofetil (CellCept), or azathioprine (Imuran) are often used to modulate the immune system.


• Calcineurin Inhibitors: Cyclosporine (Neoral) or tacrolimus (Prograf) are effective for specific inflammatory profiles.


• Biologic Response Modifiers: For severe or refractory cases, TNF-alpha inhibitors like adalimumab (Humira) or infliximab (Remicade) have become essential tools in managing systemic inflammatory uveitis.


• Local Injections: Sustained-release corticosteroid implants (such as dexamethasone intravitreal implants or fluocinolone acetonide) can deliver medication directly to the site of inflammation.

Are there surgical or non-pharmacological interventions?

Surgery is generally reserved for complications arising from chronic uveitis rather than the inflammation itself. Common procedures include cataract surgery, which is often complicated by the underlying inflammation, or vitrectomy for patients with persistent vitreous haze. For some patients, physical therapy may be helpful if the uveitis is associated with systemic conditions like ankylosing spondylitis, where joint mobility and posture are compromised.

Which specialists should be on my care team?

Because uveitis is frequently linked to systemic autoimmune diseases, a multidisciplinary approach is vital. Your care team should ideally include:

1. Uveitis Specialist/Ophthalmologist: To manage the ocular inflammation and vision health.


2. Rheumatologist: To identify and treat underlying systemic autoimmune triggers.


3. Infectious Disease Specialist: To rule out infectious causes such as tuberculosis, syphilis, or Lyme disease.


4. Clinical Geneticist: To assess hereditary links if the condition is associated with specific human leukocyte antigen (HLA) markers like HLA-B27.

Next steps

• Consult a fellowship-trained uveitis specialist or a retina specialist to ensure a precise diagnosis of the anatomical type of your condition.


• Join the 135 community members on DiseaseMaps.org to share experiences and learn how others manage their treatment protocols.


• Maintain a detailed symptom diary to track flares, which can help your physician adjust your medication regimen effectively.


• Ask your doctor if you are a candidate for ongoing clinical trials regarding novel biologic therapies for non-infectious uveitis.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult with your healthcare provider for personalized treatment plans and dosages.

References

• National Eye Institute (NEI) - Uveitis Information Page


• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Portal for rare diseases and orphan drugs


• American Uveitis Society (AUS) clinical guidelines